The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China, 450052
Location status: Recruiting
NCT Number: NCT06869694
Accurate preoperative prediction of risk stratification, treatment response, and survival prognosis in gastric cancer is important for improving clinical treatment decisions, prolonging patient survival, and improving patient quality of life. The purpose of this study is to investigate the performance of the multi-parametric magnetic resonance imaging (mpMRI) and Dual-/Muti-energy CT and photon-counting Detector CT(PCD-CT) in the diagnosis and management of gastric cancer.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Zhengzhou, China, 450052
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
mpMRI and Photon-counting Detector CT scan
Time frame: 3years
Accuracy for both imaging techniques in the prediction of treatment response of gastric cancer.
Time frame: 1year
Consistency of the Photon-counting Detector CT and mpMRI in tumor assessment
Contact information is provided by the study sponsor or research team.
The First Affiliated Hospital of Zhengzhou University
Other
Diagnostic and Predictive Performance of Dual-/ Muti- Energy CT and MRI in the Treatment Response and Survival Prognosis of Gastric Cancer
Acronym: CTIDGC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04107077
Abdominal Neoplasms, Digestive System Diseases
Chicago, Illinois, United States
View Trial DetailsNCT06172478
Adnexal Diseases, Advanced Solid Tumor
Duarte, California, United States
View Trial DetailsNCT03219593
Apatinib, Biomarker
Bengbu, Anhui, China
View Trial DetailsNCT06904365
Anal Cancer, Anus Diseases
St Louis, Missouri, United States
View Trial Details